Traws Pharma Inc Dossier
Qualitative Analysis
Business overview
Traws Pharma, Inc. (NASDAQ: TRAW), formerly known as Onconova Therapeutics, Inc., is a clinical-stage biopharmaceutical company dedicated to developing novel, oral small-molecule therapies to target critical threats to human health in respiratory viral diseases. Following its strategic merger with Trawsfynydd Therapeutics, Inc. in April 2024, the company pivoted its primary focus from oncology to virology. Traws Pharma's lead investigational programs include tivoxavir marboxil (TXM), an oral CAP-dependent endonuclease inhibitor designed as a single-dose treatment or once-monthly prophylactic agent for seasonal and H5N1 avian influenza, and ratutrelvir, a ritonavir-independent oral 3CL protease inhibitor in development for COVID-19. The company also maintains legacy oncology assets, narazaciclib and rigosertib, which it is actively positioning for external development and commercialization partnerships.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning the company's core focus from legacy oncology programs to oral small molecule antiviral therapies targeting respiratory viral diseases, including seasonal influenza, H5N1 avian influenza, COVID-19, and hantavirus.
Expected impact: Positions the company to address high-fatality and high-prevalence viral threats, targeting multi-billion dollar market opportunities in pandemic preparedness and seasonal prophylaxis.
Actively seeking development and commercialization partners for legacy oncology assets, specifically rigosertib and narazaciclib, to bring in non-dilutive capital and optimize operational focus.
Expected impact: Reduces oncology-related R&D expenses while potentially generating non-dilutive funding to support the core virology pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To combine Onconova's clinical-stage oncology capabilities with Trawsfynydd's next-generation oral small molecule antiviral portfolio, creating a diversified clinical-stage biopharmaceutical entity renamed Traws Pharma, Inc.
Financial impact: Resulted in a non-cash in-process R&D charge of $117.5 million in Q2 2024 and shifted the combined company's primary strategic focus to virology.
Strategic Partnerships
Provides Traws Pharma with an exclusive, royalty-free, sublicensable, worldwide license to certain Viriom patents and technical IP to develop novel compounds for viral diseases, alongside ongoing virology research services.
Terms: Royalty-free license; ongoing service fees under a Master Research and Development Agreement.
The mutual termination of this legacy oncology license agreement in April 2025 marked the company's formal exit from active oncology development to prioritize its antiviral pipeline.
Terms: Led to the recognition of $2.8 million in deferred revenue during fiscal year 2025.